...
首页> 外文期刊>Recent Patents on CNS Drug Discovery >Protein Kinase C Pharmacology: Perspectives on Therapeutic Potentials as Antidementic and Cognitive Agents
【24h】

Protein Kinase C Pharmacology: Perspectives on Therapeutic Potentials as Antidementic and Cognitive Agents

机译:蛋白激酶C药理学:作为抗痴呆剂和认知剂的治疗潜力的观点。

获取原文
获取原文并翻译 | 示例
           

摘要

Activity of protein kinase C (PKC) isozymes plays a critical role in various types of learning and memory. In addition, abnormal functions of PKC signal cascades in neurons represent one of the earliest changes in the brains of patients with Alzheimer's disease (AD) and dementia related to ischemic/stroke events. In preclinical studies, inhibition or impairment of PKC activity leads to compromised learning and memory, whereas an appropriate activation of PKC isozymes has been found to enhance learning and memory and/or to produce antidementic effects. The PKC activators not only increase activity of PKC isozymes and thereby restore PKC signaling activity but also reduce the accumulation of neurotoxic amyloid and tau protein hyperphosphorylation in the brain. These observations strongly suggest that PKC pharmacology may represent an attractive area for the development of cognitive therapeutics and agents against dementia in the future.
机译:蛋白激酶C(PKC)同工酶的活性在各种类型的学习和记忆中起着至关重要的作用。此外,神经元中PKC信号级联的异常功能代表阿尔茨海默氏病(AD)和与缺血/中风事件有关的痴呆症患者大脑中最早的变化之一。在临床前研究中,抑制或破坏PKC活性会导致学习和记忆受损,而已发现适当激活PKC同工酶可增强学习和记忆能力和/或产生抗痴呆作用。 PKC激活剂不仅可以增加PKC同工酶的活性,从而恢复PKC信号活性,而且可以减少神经毒性淀粉样蛋白的积累和tau蛋白在大脑中的过度磷酸化。这些观察结果强烈表明,PKC药理学可能代表着将来开发认知疗法和抗痴呆症药物的诱人领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号